Qiagen (NYSE:QGEN) Sees Large Volume Increase – Here’s Why

Qiagen N.V. (NYSE:QGEN) saw unusually-high trading volume on Monday . 3,107,377 shares were traded during mid-day trading, an increase of 23% from the previous session’s volume of 2,521,901 shares.The stock last traded at $42.6950 and had previously closed at $44.07.

Wall Street Analyst Weigh In

Several research firms have issued reports on QGEN. Zacks Research raised shares of Qiagen from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 29th. Morgan Stanley raised shares of Qiagen from an “overweight” rating to an “overweight” rating and boosted their price objective for the company from $40.00 to $42.00 in a research report on Tuesday, June 23rd. Kepler Capital Markets set a $38.60 price objective on shares of Qiagen and gave the company a “hold” rating in a research note on Thursday, June 25th. Citigroup restated a “neutral” rating and set a $45.00 target price (up from $38.00) on shares of Qiagen in a research report on Monday, August 10th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $43.93.

Qiagen Stock Down 3.5%

The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The company has a market cap of $8.76 billion, a PE ratio of 21.83, a PEG ratio of 4.39 and a beta of 0.63. The firm has a fifty day simple moving average of $40.75 and a 200 day simple moving average of $40.88.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The company had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The company’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities research analysts predict that Qiagen N.V. will post 2.43 EPS for the current year.

Hedge Funds Weigh In On Qiagen

Institutional investors and hedge funds have recently bought and sold shares of the stock. United Services Automobile Association purchased a new position in Qiagen during the first quarter worth approximately $239,000. Prudential Financial Inc. grew its stake in shares of Qiagen by 74.9% during the 2nd quarter. Prudential Financial Inc. now owns 8,873 shares of the company’s stock valued at $426,000 after buying an additional 3,799 shares during the period. Invesco Ltd. grew its stake in shares of Qiagen by 123.7% during the 2nd quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock valued at $48,350,000 after buying an additional 556,387 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Qiagen by 226.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock worth $125,000 after buying an additional 1,802 shares during the last quarter. Finally, First Trust Advisors LP acquired a new stake in shares of Qiagen during the 2nd quarter worth $3,639,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.